Recent

% | $
Quotes you view appear here for quick access.

công ty Avanir Pharmaceuticals Message Board

  • greatdayforinvestments greatdayforinvestments Feb 4, 2013 2:29 PM Flag

    Piper Jaffray

    Nuedexta prescriptions are growing well, but poised to accelerate over 1-4 quarters with an increasingly effective institutional force and recently re-targeted retail effort. We believe the market under-appreciates Nuedexta's broad applicability...

    “We are initiating on Avanir with an Overweight rating and $6 price target. Avanir develops drugs for neurological diseases with one product, Nuedexta, approved for pseudobulbar affect (PBA), marketed by possibly one of the largest institutionalized-patient-focused sales forces in the U.S. Its Nuedexta-derived pipeline should lower capital and clinical-failure risk, in our view. Nuedexta prescriptions are growing well, but poised to accelerate over 1-4 quarters with an increasingly effective institutional force and recently re-targeted retail effort. We believe the market under-appreciates Nuedexta's broad applicability that supports use in settings like MS-pain and Alzheimer's agitation, both in PhII trials that we expect to become increasingly visible on enrollment updates and data, fueling AVNR appreciation in later 2013 to 1H'14.”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AVNR
16.960.00(0.00%)Jan 12 3:59 PMEST